Go Pro
→ Iran War WARNING: Something Just Changed (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.37
$0.26
$0.12
▼
$3.00
N/AN/A4,478 shs46 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
$0.01
$0.01
▼
$0.23
N/AN/A55,136 shs10 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
$0.01
-2.0%		$0.02
$0.00
▼
$0.20
N/AN/A73,112 shs3,544 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%-7.50%+117.14%-77.16%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%0.00%-19.44%-11.45%-39.27%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
-2.03%-3.97%-46.69%+5.84%-50.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.37
$0.26
$0.12
▼
$3.00
N/AN/A4,478 shs46 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
$0.01
$0.01
▼
$0.23
N/AN/A55,136 shs10 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
$0.01
-2.0%		$0.02
$0.00
▼
$0.20
N/AN/A73,112 shs3,544 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%0.00%-7.50%+117.14%-77.16%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%0.00%-19.44%-11.45%-39.27%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
-2.03%-3.97%-46.69%+5.84%-50.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$491.95MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$8.50MN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/A11/11/2026 (Estimated)
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
N/AN/AN/AN/AN/AN/AN/AN/A11/17/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
35.80%
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
60.40%
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
4N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
59N/AN/ANot Optionable
Aravive, Inc stock logo
ARAV
Aravive
20N/AN/ANo Data
SAB Biotherapeutics, Inc. stock logo
SABSW
SAB Biotherapeutics
140N/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.37 0.00 (0.00%)
As of 09/25/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.01 0.00 (0.00%)
As of 09/25/2026

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 09/25/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

SAB Biotherapeutics stock logo

SAB Biotherapeutics NASDAQ:SABSW

$0.01 0.00 (-2.03%)
As of 09/25/2026 02:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas